Ertugliflozin 10 mg

DRUG4 trials

Conditions

Type 2 Diabetes Mellitus

Phase 3

A Study of the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise (MK-8835-003, VERTIS MONO)

CompletedNCT01958671

Merck Sharp & Dohme LLCType 2 Diabetes Mellitus

Start: 2013-10-09End: 2016-07-28Updated: 2017-09-29

A Study of the Efficacy and Safety of Ertugliflozin in Participants With Type 2 Diabetes Mellitus With Stage 3 Chronic Kidney Disease Who Have Inadequate Glycemic Control on Antihyperglycemic Therapy (MK-8835-001)

CompletedNCT01986855

Merck Sharp & Dohme LLCType 2 Diabetes Mellitus

Start: 2013-12-02End: 2016-09-28Updated: 2018-09-10

Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002)

CompletedNCT01999218

Merck Sharp & Dohme LLCType 2 Diabetes Mellitus

Start: 2013-12-16End: 2017-04-18Updated: 2019-04-02

Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)

CompletedNCT02099110

Merck Sharp & Dohme LLCType 2 Diabetes Mellitus

Start: 2014-04-22End: 2016-05-26Updated: 2018-09-12

Expert Opinion on Pharmacotherapy2021-06-164 citations

The effects of ertugliflozin on β‐cell function: Pooled analysis from four phase 3 randomized controlled studies

Diabetes Obesity and Metabolism2020-07-236 citations

Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 Trials

Diabetes Therapy2020-07-0914 citations

Safety of Ertugliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Seven Phase 3 Randomized Controlled Trials.

2020-05-0518 citations

Efficacy and safety of ertugliflozin across racial groups in patients with type 2 diabetes mellitus

Current Medical Research and Opinion2020-04-2310 citations

Efficacy and safety of ertugliflozin in Hispanic/Latino patients with type 2 diabetes mellitus

Current Medical Research and Opinion2020-04-233 citations

Effects of ertugliflozin on renal function over 104 weeks of treatment: a post hoc analysis of two randomised controlled trials

Diabetologia2020-03-3140 citations

Efficacy and safety of ertugliflozin in East/Southeast Asian patients with type 2 diabetes mellitus.

2020-01-039 citations

Efficacy of ertugliflozin in monotherapy or combination therapy in patients with type 2 diabetes: A pooled analysis of placebo-controlled studies

Diabetes and Vascular Disease Research2019-05-1325 citations

Effect of ertugliflozin on blood pressure in patients with type 2 diabetes mellitus: a post hoc pooled analysis of randomized controlled trials

Cardiovascular Diabetology2019-05-0720 citations

Results of VERTIS SU extension study: safety and efficacy of ertugliflozin treatment over 104 weeks compared to glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin

Current Medical Research and Opinion2019-02-1450 citations

Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study.

2018-02-2363 citations

Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial.

2018-01-25118 citations

Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study

Diabetes Therapy2017-12-27106 citations

Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study.

2017-11-20111 citations

Ertugliflozin 10 mg

Sponsors

Conditions

Phase 3

Related Papers